Stem cell transplant and idiotypic vaccination for B-cell malignancies

Current Topics in Medicinal Chemistry

Volumn 11, Issue 13, 2011, Pages 1653-1660

  Inoges, Susana ^a,b   de Cerio, Ascension Lopez Diaz ^b   Sampol, Antonia ^c   Nieto, Jose ^d   Soria, Elena ^b   Villanueva, Helena ^b   Pastor, Fernando ^b   Bendandi, Maurizio ^a,b,e  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Allogeneic; Autologous; Idiotypic vaccination; Lymphoma; Myeloma; Stem cell transplant

Indexed keywords

CANCER VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; PARAPROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADJUVANT THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER RELAPSE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DONOR; DRUG EFFICACY; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE MUTATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; GRAFT VERSUS MYELOMA EFFECT; HEALTH CARE QUALITY; HUMAN; HUMORAL IMMUNITY; IDIOTYPIC VACCINATION; IMMUNE SYSTEM; LARGE CELL LYMPHOMA; MULTIPLE MYELOMA; PASSIVE IMMUNIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); POLYCLONAL ACTIVATION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTRATION; REVIEW; T LYMPHOCYTE; TUMOR CELL;

B-LYMPHOCYTES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, FOLLICULAR; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; VACCINATION;

EID: 79959550937     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796117676     Document Type: Review

References (50)

1. McKenna, R.W.; Kyle, R.A.; Kuehl, W.M.; Grogan, T.M.; Harris, N.L.; Coupland, R.W. Plasma cell neoplasms. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W. Eds.; International Agency for Research on Cancer: Lyon, 2008; pp. 200-213.
2. Harris, N.L.; Swerdlow, S.H.; Jaffe, E.S.; Ott, G.; Nathwani, B.N.; de Jong, D.; Yoshino, T.; Spagnolo, D. Follicular lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W. Eds.; International Agency for Research on Cancer: Lyon, 2008; pp. 220-227.
3. Stein, H.; Warnke, R.A.; Chan, W.C.; Jaffe, E.S.; Chan, J.K.C.; Gatter, K.C.; Campo, E. Diffuse large B-cell lymphoma, not otherwise specified. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W. Eds.; International Agency for Research on Cancer: Lyon, 2008; pp. 233-237.
4. Swerdlow, S.H.; Campo, E.; Seto, M.; Mueller-Hermelink, H.K. Mantle cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W., Eds.; International Agency for Research on Cancer: Lyon, 2008; pp. 229-232.
5. Inoges, S.; de Cerio, A.L.; Soria, E.; Villanueva, H.; Pastor, F.; Bendandi, M. Idiotype vaccines for B-cell malignancies. Curr. Pharm. Des., 2010, 16, 300-307.
6. Treleaven, J.; Barrett, A.J. Hematopoietic Stem Cell Transplantation in Clinical Practice; Elsevier: Philadelphia, 2008.
7. Bendandi, M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer, 2009, 9, 675-681.
8. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twentyfirst century: a population-based study. J. Clin. Oncol., 2010, 28, 830-834.
9. Bladé, J.; Rosiñol, L.; Cibeira, M.T.; Rovira, M.; Carreras, E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood, 2010,115(18),3655-3663.
10. Coiffier, B. Rituximab therapy in malignant lymphoma. Oncogene, 2007, 26, 3603-3613.
11. Foster, M.; Gabriel. D.A.; Shea, T. Role of hematopoietic stem cell transplant in the management of follicular lymphoma. Oncologist, 2009, 14, 726-738.
12. Thieblemont, C.; Gisselbrecht, C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr. Oncol. Rep., 2009, 11, 386-393.
13. Li, Y.; Bendandi, M.; Deng, Y.; Dunbar, C.; Munshi, N.; Jagannath, S.; Kwak, L.W.; Lyerly, H.K. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood, 2000, 96, 2828-2833.
14. Longo, D.L. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl. Cancer Inst., 2006, 98, 1263-1265.
15. Bendandi, M. Aiming at a curative strategy for follicular lymphoma. CA-Cancer J. Clin., 2008, 58, 305-317.
16. Bendandi, M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Ther., 2001, 1, 65-72.
17. Bendandi, M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev. Vaccines, 2004, 3, 163-170.
18. Baskar, S.; Kobrin, C.B.; Kwak, L.W. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J. Clin. Invest., 2004, 113, 1498-1510.
19. Raffeld, M.; Neckers, L.; Longo, D.L.; Cossman, J. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. N. Engl. J. Med., 1985, 312, 1653-1658.
20. Meeker, T.; Lowder, J.; Cleary, M.L.; Stewart, S.; Warnke, R.; Sklar, J.; Levy, R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med., 1985, 312, 1658-1665.
21. Kobrin, C.B.; Bendandi, M.; Kwak, L.W. Novel secondary Ig VH gene rearrangement and in-frame Ig heavy chain complementaritydetermining region III insertion/deletion variants in de novo follicular lymphoma. J. Immunol., 2001, 166, 2235-2243.
22. Carroll, W.L.; Thielemans, K.; Dilley, J.; Levy, R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods, 1986, 89, 61-72.
23. Rodríguez-Calvillo, M.; Inogés, S.; López-Díaz de Cerio, A.; Zabalegui, N.; Villanueva, H.; Bendandi, M. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit. Rev. Oncol. Hematol., 2004, 52, 1-7.
24. Timmerman, J.M.; Czerwinski, D.K.; Davis, T.A.; Hsu, F.J.; Benike, C.; Hao, Z.M.; Taidi, B.; Rajapaksa, R.; Caspar, C.B.; Okada, C.Y.; van Beckhoven, A.; Liles, T.M.; Engleman, E.G.; Levy, R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 2002, 99, 1517-1526.
25. Curti, A.; Tosi, P.; Comoli, P.; Terragna, C.; Ferri, E.; Cellini, C.; Massaia, M.; D'Addio, A.; Giudice, V.; Di Bello, C.; Cavo, M.; Conte, R.; Gugliotta, G.; Baccarani, M.; Lemoli, R.M. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haematol., 2007, 139, 415-424.
26. Bendandi, M.; Rodríguez-Calvillo, M.; Inogés, S.; López-Díaz de Cerio, A.; Pérez-Simón, J.A.; Rodríguez-Caballero, A.; García-Montero, A.; Almeida, J.; Zabalegui, N.; Giraldo, P.; San Miguel, J.; Orfao, A. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma, 2006, 47, 29-37.
27. Inoges, S.; Lopez-Diaz de Cerio, A.; Zabalegui, N.; Soria, E.; Villanueva, H.; Panizo, C.; Rodriguez-Caballero, A.; Suarez, L.; Pastor, F.; Rodriguez-Calvillo, M.; Orfao, A.; Bendandi, M. Prolonged idiotypic vaccination against follicular lymphoma. Leuk. Lymphoma, 2009, 50, 47-53.
28. Kwak, L.W.; Young, H.A.; Pennington, R.W.; Weeks, S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA, 1996, 93, 10972-10977.
29. Kwak, L.W.; Campbell, M.J.; Czerwinski, D.K.; Hart, S.; Miller, R.A.; Levy, R. Induction of immune responses in patients with Bcell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 1992, 327, 1209-1215.
30. Bendandi, M.; Gocke, C.D.; Kobrin, C.B.; Benko, F.A.; Sternas, L.A.; Pennington, R.; Watson, T.M.; Reynolds, C.W.; Gause, B.L.; Duffey, P.L.; Jaffe, E.S.; Creekmore, S.P.; Longo, D.L.; Kwak, L.W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med., 1999, 5, 1171-1177.
31. Rasmussen, T.; Hansson, L.; Osterborg, A.; Johnsen, H.E.; Mellstedt, H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood, 2003, 101, 4607-4610.
32. Abdalla, A.O.; Kokhaei, P.; Hansson, L.; Mellstedt, H.; Osterborg, A. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann. Oncol., 2008, 19, 1172-1179.
33. Inogès, S.; Rodrìguez-Calvillo, M.; Zabalegui, N.; Lòpez-Dìaz de Cerio, A.; Villanueva, H.; Soria, E.; Suárez, L.; Rodríguez-Caballero, A.; Pastor, F.; García-Muñóz, R.; Panizo, C.; Pèrez-Calvo, J.; Melero, I.; Rocha, E.; Orfao, A.; Bendandi, M. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl. Cancer Inst., 2006, 98, 1292-1301.
34. Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev. Recent Clin. Trials, 2006, 1, 67-74.
35. Lopez-de Cerio, A.; Inoges, S. Future of idiotypic vaccination for B-cell lymphoma. Expert Rev. Vaccines, 2009, 8, 43-50.
36. Reichardt, V.L.; Okada, C.Y.; Liso, A.; Benike, C.J.; Stockerl-Goldstein, K.E.; Engleman, E.G.; Blume, K.G.; Levy, R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood, 1999, 93, 2411-2419.
37. Massaia, M.; Borrione, P.; Battaglio, S.; Mariani, S.; Beggiato, E.; Napoli, P.; Voena, C.; Bianchi, A.; Coscia, M.; Besostri, B.; Peola, S.; Stiefel, T.; Even, J.; Novero, D.; Boccadoro, M.; Pileri, A. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood, 1999, 94, 673-683.
38. Coscia, M.; Mariani, S.; Battaglio, S.; Di Bello, C.; Fiore, F.; Foglietta, M.; Pileri, A.; Boccadoro, M.; Massaia, M. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 2004, 18, 139-145.
39. Lacy, M.Q.; Mandrekar, S.; Dispenzieri, A.; Hayman, S.; Kumar, S.; Buadi, F.; Dingli, D.; Litzow, M.; Wettstein, P.; Padley, D.; Kabat, B.; Gastineau, D.; Rajkumar, S.V.; Gertz, M.A. Idiotypepulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am. J. Hematol., 2009, 84, 799-802.
40. Davis, T.A.; Hsu, F.J.; Caspar, C.B.; van Beckhoven, A.; Czerwinski, D.K.; Liles, T.M.; Taidi, B.; Benike, C.J.; Engleman, E.G.; Levy, R. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol. Blood Marrow Transpl., 2001, 7, 517-522.
41. Kwak, L.W.; Taub, D.D.; Duffey, P.L.; Bensinger, W.I.; Bryant, E.M.; Reynolds, C.W.; Longo, D.L. Transfer of myeloma idiotypespecific immunity from an actively immunised marrow donor. Lancet, 1995, 345, 1016-1020.
42. Neelapu, S.S.; Munshi, N.C.; Jagannath, S.; Watson, T.M.; Pennington, R.; Reynolds, C.; Barlogie, B.; Kwak, L.W. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transpl., 2005, 36, 315-323.
43. Cabrera, R.; Díaz-Espada, F.; Barrios, Y.; Briz, M.; Forés, R.; Barbolla, L.; Sanjuan, I.; Regidor, C.; Peñalver, F.J.; Fernandez, M.N. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transpl., 2000, 25, 1105-1108.
44. Bendandi, M.; Rodríguez-Calvillo, M.; Inogés, S.; López-Díaz de Cerio, A.; Pérez-Simón, J.A.; Rodríguez-Caballero, A.; Garcia-Montero, A.; Almeida, J.; Zabalegui, N.; Giraldo, P.; San Miguel, J.; Orfao, A. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma, 2006, 47, 29-37.
45. http://www.clinicaltrials.gov/ct2/show/NCT00530140?term=idiotype+vaccine&rank=3 (accessed on March 24, 2010)
46. Bendandi, M.; Marillonnet, S.; Kandzia, R.; Thieme, F.; Nickstadt, A.; Herz, S.; Froede, R.; Inoges, S.; Lopez-Diaz de Cerio, A.; Soria, E.; Villanueva, H.; Vancanneyt, G.; McCormick, A.; Tuse', D.; Lenz, J.; Butler-Ransohoff, J.E.; Klimyuk, V.; Gleba, Y. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann. Oncol., 21(12), 2420-2427.
47. Zhu, D.; McCarthy, H.; Ottensmeier, C.H.; Johnson, P.; Hamblin, T.J.; Stevenson, FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 2002, 99, 2562-2568.
48. Zabalegui, N.; de Cerio, A.L.; Inogés, S.; Rodríguez-Calvillo, M.; Pérez-Calvo, J.; Hernández, M.; García-Foncillas, J.; Martín-Algarra, S.; Rocha, E.; Bendandi, M. Acquired potential Nglycosylation sites within the tumor-specific heavy chains of B-cell malignancies. Haematologica, 2004, 89, 541-546.
49. Radcliffe, C.M.; Arnold, J.N.; Suter, D.M.; Wormald, M.R.; Harvey, D.J.; Royle, L.; Mimura, Y.; Kimura, Y.; Sim, R.B.; Inogès, S.; Rodriguez-Calvillo, M.; Zabalegui, N.; de Cerio, A.L.; Potter, K.N.; Mockridge, C.I.; Dwek, R.A.; Bendandi, M.; Rudd, P.M.; Stevenson, F.K. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J. Biol. Chem., 2007, 282, 7405-7415.
50. Lopez de Cerio, A.; Zabalegui, N.; Rodríguez-Calvillo, M.; Inogés, S.; Bendandi, M. Anti-idiotype antibodies in cancer treatment. Oncogene, 2007, 26, 3594-3602.